Several studies have shown that cytotoxic T cells that recognize non-mutant epitopes in p53 can selectively kill malignant cells but not normal cells [12, 13]; therefore, non-mutant p53 may be a reasonable shared antigen for tumor-selective immunotherapy. The gene discussed is TP53; the disease is neoplasm.